Switch theme
Sign up to access all valuation multiples
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
1998
900
LTM Revenue $949M
LTM EBITDA $168M
$860M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Emergent BioSolutions has a last 12-month revenue (LTM) of $949M and a last 12-month EBITDA of $168M.
In the most recent fiscal year, Emergent BioSolutions achieved revenue of $1.0B and an EBITDA of $36.9M.
Emergent BioSolutions expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Emergent BioSolutions valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $949M | XXX | $1.0B | XXX | XXX | XXX |
| Gross Profit | $375M | XXX | $332M | XXX | XXX | XXX |
| Gross Margin | 40% | XXX | 33% | XXX | XXX | XXX |
| EBITDA | $168M | XXX | $36.9M | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 4% | XXX | XXX | XXX |
| EBIT | -$27.1M | XXX | -$81.5M | XXX | XXX | XXX |
| EBIT Margin | -3% | XXX | -8% | XXX | XXX | XXX |
| Net Profit | $6.3M | XXX | -$191M | XXX | XXX | XXX |
| Net Margin | 1% | XXX | -19% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $564M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Emergent BioSolutions's stock price is $6.
Emergent BioSolutions has current market cap of $343M, and EV of $860M.
See Emergent BioSolutions trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $860M | $343M | XXX | XXX | XXX | XXX | $0.22 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Emergent BioSolutions has market cap of $343M and EV of $860M.
Emergent BioSolutions's trades at 0.8x EV/Revenue multiple, and 23.3x EV/EBITDA.
Equity research analysts estimate Emergent BioSolutions's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Emergent BioSolutions has a P/E ratio of 54.6x.
See valuation multiples for Emergent BioSolutions and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $343M | XXX | $343M | XXX | XXX | XXX |
| EV (current) | $860M | XXX | $860M | XXX | XXX | XXX |
| EV/Revenue | 0.9x | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | 5.1x | XXX | 23.3x | XXX | XXX | XXX |
| EV/EBIT | -31.8x | XXX | -10.5x | XXX | XXX | XXX |
| EV/Gross Profit | 2.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 54.6x | XXX | -1.8x | XXX | XXX | XXX |
| EV/FCF | 6.7x | XXX | 24.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEmergent BioSolutions's last 12 month revenue growth is -8%
Emergent BioSolutions's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $0.5M for the same period.
Emergent BioSolutions's rule of 40 is -59% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Emergent BioSolutions's rule of X is -3% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Emergent BioSolutions and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -8% | XXX | -3% | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Growth | -29% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -59% | XXX | -5% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -3% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 41% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Emergent BioSolutions acquired XXX companies to date.
Last acquisition by Emergent BioSolutions was XXXXXXXX, XXXXX XXXXX XXXXXX . Emergent BioSolutions acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Emergent BioSolutions founded? | Emergent BioSolutions was founded in 1998. |
| Where is Emergent BioSolutions headquartered? | Emergent BioSolutions is headquartered in United States of America. |
| How many employees does Emergent BioSolutions have? | As of today, Emergent BioSolutions has 900 employees. |
| Who is the CEO of Emergent BioSolutions? | Emergent BioSolutions's CEO is Mr. Joseph C. Papa. |
| Is Emergent BioSolutions publicy listed? | Yes, Emergent BioSolutions is a public company listed on NYS. |
| What is the stock symbol of Emergent BioSolutions? | Emergent BioSolutions trades under EBS ticker. |
| When did Emergent BioSolutions go public? | Emergent BioSolutions went public in 2006. |
| Who are competitors of Emergent BioSolutions? | Similar companies to Emergent BioSolutions include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Emergent BioSolutions? | Emergent BioSolutions's current market cap is $343M |
| What is the current revenue of Emergent BioSolutions? | Emergent BioSolutions's last 12 months revenue is $949M. |
| What is the current revenue growth of Emergent BioSolutions? | Emergent BioSolutions revenue growth (NTM/LTM) is -8%. |
| What is the current EV/Revenue multiple of Emergent BioSolutions? | Current revenue multiple of Emergent BioSolutions is 0.9x. |
| Is Emergent BioSolutions profitable? | Yes, Emergent BioSolutions is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Emergent BioSolutions? | Emergent BioSolutions's last 12 months EBITDA is $168M. |
| What is Emergent BioSolutions's EBITDA margin? | Emergent BioSolutions's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Emergent BioSolutions? | Current EBITDA multiple of Emergent BioSolutions is 5.1x. |
| What is the current FCF of Emergent BioSolutions? | Emergent BioSolutions's last 12 months FCF is $129M. |
| What is Emergent BioSolutions's FCF margin? | Emergent BioSolutions's last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of Emergent BioSolutions? | Current FCF multiple of Emergent BioSolutions is 6.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
